Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men

Brondani, Letícia A.; Boelter, Gabriela; Assmann, Taís Silveira; Leitão, Cristiane Bauermann; Canani, Luís Henrique Santos; Crispim, Daisy

doi:10.1016/j.metabol.2015.05.005

Cited by 32 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, since the discovery of irisin, its levels have been associated with hip fractures [22], sarcopenia [23], insulin resistance [24], chronic obstructive pulmonary disease [25], chronic kidney disease (CKD) [26], and CKD stage [27]. Furthermore, irisin-encoding gene (FNDC5) variant can change blood pressure in men with type 2 diabetes [28], while irisin improves endothelial function in type 2 diabetes [29] and in a mouse model of obesity [30]. In addition, irisin protects against endothelial injury and ameliorates atherosclerosis in Apo-E knockout mice [31].…”

Section: Discussionmentioning

confidence: 99%

Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke

Qiu

Cao

et al. 2018

Neurotherapeutics

View full text Add to dashboard Cite

Irisin was discovered as a PGC-1a-activated messenger of myocytes that links sedentary lifestyle, obesity, and diabetes. In this study, we investigated the short-term prognostic value of early measurement of irisin concentration in 1530 Han Chinese patients with acute ischemic stroke (AIS) from three stroke centers. The subjects were the first-ever AIS patients who were hospitalized at three stroke centers during the period from January 2015 to December 2016. Clinical information and stroke severity were collected at admission. Neurological evaluations were conducted at the 6-month follow-up. Serum levels of irisin, National Institutes of Health Stroke Scale (NIHSS), and conventional risk factors were evaluated to determine their value to predict functional outcome and mortality within 6 months. Multivariate analyses were performed using logistic regression models. During follow-up, a poor functional outcome was found in 588 patients (38.4%; 95% confidence interval (CI), 36.0-40.9%), and 325 patients died (21.2%; 95% CI, 19.2-23.3%). The stroke patients included in the study were divided into four groups according to irisin quartiles (first is the lowest level). Poor outcome across the irisin quartiles ranged from 54.5% (first quartile) to 21.7% (fourth quartile), and mortality rate ranged from 39.3% (first quartile) to 6.3% (fourth quartile). In a multivariate model using the first quartile (Q1) of irisin vs. Q2-Q4 together with the clinical variables, the marker displayed prognostic information and increased odds ratios of poor outcome by 58% (OR for Q1, 1.58 [95% CI, 1.12-2.43]) and mortality by 185% (OR for Q1, 2.85 [95% CI, 1.79-4.02]). In addition, a model containing known risk factors plus irisin compared with a model containing known risk factors without irisin showed a greater discriminatory ability to predict poor outcome (the area under the curve (AUC) with an increase from 0.73 to 0.75 [95% CI, 0.70-0.81]) and mortality (the AUC increased from 0.80 to 0.83 [95% CI, 0.78-0.87]). Irisin is a novel, independent prognostic marker improving currently used risk stratification of stroke patients. Further studies are needed to confirm this association, which may pave the way to new therapeutic options. Trial registration: ChiCTR-OPC- 17013501.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke

Qiu

Cao

et al. 2018

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Irisin is a novel myokine that is considered a muscle-derived energy-expenditure signal secreted from the skeletal muscle after cleavage of the myokine fibronectin type III domain containing 5 (FNDC5) in response to exercise and/or peroxisome proliferator-activated receptor-γ coactivation 1a (PGC-1a) [ 44 ]. A diverse array of metabolic actions has been associated with irisin levels [ 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 ]. Irisin levels correlate positively with markers of adiposity, are increased in obesity and irisin resistance might develop in obese individuals [ 67 68 69 70 ].…”

Section: Novel Molecules Important In Energy Homeostasismentioning

confidence: 99%

Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss

Gavrieli

Mantzoros

2016

Endocrinol Metab

View full text Add to dashboard Cite

Excess energy intake, without a compensatory increase of energy expenditure, leads to obesity. Several molecules are involved in energy homeostasis regulation and new ones are being discovered constantly. Appetite regulating hormones such as ghrelin, peptide tyrosine-tyrosine and amylin or incretins such as the gastric inhibitory polypeptide have been studied extensively while other molecules such as fibroblast growth factor 21, chemerin, irisin, secreted frizzle-related protein-4, total bile acids, and heme oxygenase-1 have been linked to energy homeostasis regulation more recently and the specific role of each one of them has not been fully elucidated. This mini review focuses on the above mentioned molecules and discusses them in relation to their regulation by the macronutrient composition of the diet as well as diet-induced weight loss.

show abstract

“…In another cross-sectional study, Brondani et al [17] investigated the association of FNDC5 rs3480 (A/G) and rs1746661 (G/T) polymorphisms with clinical characteristics in 1,006 patients with type 2 diabetes (T2DM) and 434 nondiabetic subjects. They found that the T allele of rs1746661 was associated with increased systolic BP and not diastolic BP, but only in women with diabetes.…”

Section: Irisin and Blood Pressurementioning

confidence: 99%

Hypertension and beyond — does circulating irisin matter?

Taszarek

Kaczmarkiewicz

Miazgowski

2016

Arterial Hypertension

View full text Add to dashboard Cite

Irisin is a myokine secreted by skeletal muscles. It has been proposed to drive the brown-fat-like conversion of the white adipose tissue. By enhancing energy expenditure, irisin may affect systemic metabolism and be associated with insulin resistance; however, the mechanism(s) of action still remain largely unexplained. The discovery of irisin can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of metabolic diseases or metabolism-associated health issues. In this review, based on the recent literature (from 2013 to 2015 inclusive), we will systematically discuss the associations of irisin with obesity, type 2 diabetes, lipid disorders, and hypertension. We also introduce unanswered questions for future research.

show abstract

Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men

Abstract: These results indicate that, although not associated with T2DM, the G allele of rs3480 appears to be associated with increased HbA1c, while the T allele of rs1746661 appears to be associated with higher systolic blood pressure and dyslipidemia in women with T2DM.

Cited by 32 publications

References 27 publications

Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke

Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke

Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss

Hypertension and beyond — does circulating irisin matter?

Contact Info

Product

Resources

About